- Telehealth Visits
- Insurances Accepted
Wade S. Smith, MD
Neurocritical Care • NeurologyDirector, UCSF Neurovascular Service- Telehealth Visits
- Insurances Accepted
Wade S. Smith, MD
Neurocritical Care • NeurologyDirector, UCSF Neurovascular Service- Telehealth Visits
- Insurances Accepted
On this page
About me
Dr. Wade Smith, director of the UCSF Neurovascular Service, specializes in stroke prevention, management of acute stroke, critical care medicine and medical management after stroke. He has expertise in transcranial Doppler techniques for cerebral blood-flow monitoring. As a neurointensivist – a specialist in both critical care and neurology – he directs UCSF's 16-bed neurological intensive care unit, dedicated to patients with neurological injuries. He evaluates many patients who have been referred for a second or third opinion, though he also evaluates patients who are seeing a neurologist for the first time.
Smith earned both his medical degree and a doctorate in neurophysiology from the University of Washington. He completed a residency as well as a fellowship in critical care medicine at UCSF.
Education
Board Certification
- Neurology, American Board of Psychiatry and Neurology
Fellowship
- Critical Care Anesthesia, UCSF School of Medicine -GME
Residency
- Neurology, UCSF School of Medicine -GME
Internship
- Internal Medicine, UCSF School of Medicine -GME
School
- MD, University of Washington
Academic Title
- Clinical Professor
Care Keywords
Services
- Neurocritical Care
- Neurology
- Neurology (Vascular Neurology)
Conditions
- Stroke
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.